To investigate whether GPS-induced improvements of the symptoms of type 2 diabetes were associated with the inhibition of gluconeogenesis, the expression levels of PEPCK and G6Pase were evaluated using immunohistochemistry and Western blotting assays. This evidence concerns the gene G6PC1 and type 2 diabetes mellitus.